Savara Inc. (SVRA)
| Market Cap | 1.27B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -118.84M |
| Shares Out | 253.52M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,988 |
| Open | 5.16 |
| Previous Close | 5.16 |
| Day's Range | 5.02 - 5.31 |
| 52-Week Range | 1.89 - 7.01 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 7.33 (+46.02%) |
| Earnings Date | May 13, 2026 |
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for SVRA stock is "Buy." The 12-month stock price target is $7.33, which is an increase of 46.02% from the latest price.
News
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new empl...
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended th...
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two ...
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the MHRA has accepted t...
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated t...
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth qu...
Savara Transcript: The Citizens Life Sciences Conference 2026
MOLBREEVI, an inhaled therapy for autoimmune PAP, is under FDA review with strong phase III results and a potential August approval. Commercial launch plans target 5,500 U.S. patients, supported by robust diagnostics, a focused sales force, and a narrowed pricing band of $400,000–$500,000 per year.
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the “Company”) (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the D...
Savara Announces Participation in 2026 Citizens Life Sciences Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the manage...
Savara Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Molbreevi is under FDA priority review for aPAP, with a PDUFA date set for August 22nd, and parallel filings planned in the EU and UK. The therapy addresses a significant unmet need, targeting all 5,500 diagnosed US patients, and launch preparations include a focused field force and exclusive specialty pharmacy partnership.
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the B...
Savara Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
MOLBREEVI is on track for FDA priority review with a potential August approval, supported by strong phase III data and a robust commercial strategy targeting a concentrated rare disease market. European filings are imminent, and the company is well-funded for independent launches.
Savara Announces Participation in Upcoming Investor Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its manage...
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan an...
Savara Transcript: 44th Annual J.P. Morgan Healthcare Conference
MOLBREEVI, a novel inhaled biologic for autoimmune PAP, showed strong efficacy and safety in phase III trials and is under FDA review, with US approval targeted for August. The company is scaling diagnostics, commercial infrastructure, and expects robust market access at a $400,000–$500,000 price point.
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
LANGHORNE, Pa.--(BUSINESS WIRE)--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a ...
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the ...
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the manage...
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company...
Savara Transcript: Evercore ISI 8th Annual HealthCONx Conference
Focused on rare lung disease, the company is advancing Molbreevi for autoimmune PAP, with strong Phase 3 data and regulatory filings imminent. The product offers a significant clinical benefit, a favorable safety profile, and is targeting a $400,000–$500,000 annual price point.
Savara Transcript: Piper Sandler 37th Annual Healthcare Conference
MOLBREEVI's BLA resubmission is on track for December, with a U.S. launch targeted for next year and European filings planned by Q1. The team is prepared for a robust commercial rollout, supported by strong patient identification efforts, favorable payer feedback, and a solid financial position.
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) h...
Savara Transcript: Jefferies London Healthcare Conference 2025
Molrivi, an inhaled biologic for autoimmune PAP, is on track for US and EU/UK filings, with a US launch targeted for late next year. Market analysis shows at least 5,500 US patients and strong pricing power, while robust clinical data and early commercial preparations support a confident launch.
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third qua...
Savara Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
MOLBREEVI, an inhaled biologic for autoimmune PAP, is set for BLA resubmission in December after resolving FDA manufacturing concerns. Positive IMPALA-2 trial results and expanded US patient estimates support a robust commercial strategy, with a potential launch expected after an August PDUFA date.